Login
- Title:
Neurotrophin-3 (NT-3) as a Potential Biomarker of the Peripheral Nervous System Damage Following Breast Cancer Treatment.
- Document type:
- Journal Article
- Author(s):
- Tonyan, Samvel; Pospelova, Maria; Krasnikova, Varvara; Fionik, Olga; Alekseeva, Tatyana; Samochernykh, Konstantin; Ivanova, Nataliya; Vavilova, Tatyana; Vasilieva, Elena; Makhanova, Albina; Nikolaeva, Aleksandra; Bukkieva, Tatyana; Combs, Stephanie; Shevtsov, Maxim
- Abstract:
- Damage to the peripheral nervous system (PNS) is a common complication of breast cancer (BC) treatment, with 60 to 80% of breast cancer survivors experiencing symptoms of PNS damage. In the current study, the levels of brain-derived neurotrophic factor (BDNF), galectin-3 (Gal-3), and neurotrophin-3 (NT-3) were measured in the blood serum of BC patients by ELISA as potential biomarkers that might indicate the PNS damage. Sixty-seven patients were enrolled in this multi-center trial and compared to the aged-matched healthy female volunteers (control group) (n = 25). Intergroup comparison of biomarker levels (i.e., Gal-3 and BDNF) did not show significant differences in any of the studied subgroups. However, intriguingly, NT-3 levels were significantly higher in BC patients as compared to healthy volunteers, constituting 14.85 [10.3; 18.0] and 5.74 [4.56; 13.7] pg/mL, respectively (p < 0.001). In conclusion, NT-3 might be employed as a potential biomarker in BC patients with clinical manifestations of PNS damage. However, further studies to validate its correlation to the degree of peripheral nervous system lesions are of high value.
- Journal title abbreviation:
- Pathophysiology
- Year:
- 2023
- Journal volume:
- 30
- Journal issue:
- 2
- Pages contribution:
- 110-122
- Fulltext / DOI:
- doi:10.3390/pathophysiology30020010
- Pubmed ID:
- http://view.ncbi.nlm.nih.gov/pubmed/37092524
- Print-ISSN:
- 0928-4680
- TUM Institution:
- Klinik und Poliklinik für RadioOnkologie und Strahlentherapie (Prof. Combs)
BibTeX